Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Efficacy and safety of Exforge and Aimix in hypertensives

Trial Profile

Efficacy and safety of Exforge and Aimix in hypertensives

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2015

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amlodipine/irbesartan (Primary) ; Amlodipine/valsartan (Primary)
  • Indications Essential hypertension
  • Focus Therapeutic Use
  • Most Recent Events

    • 18 Mar 2015 Status changed from active, no longer recruiting to completed as reported by University Hospital Medical Information Network - Japan record.
    • 28 Feb 2015 Status changed from recruiting to active, no longer recruiting according to University Hospital Medical Information Network - Japan record.
    • 20 Sep 2014 Planned number of patients changed from 80 to 60 as reported by University Hospital Medical Information Network - Japan
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top